A Prospective, Multicentre Trial to Assess the safety and effectiveness of an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Lesion in a Small Vessel (2.25 - 2.5mm diameter)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis
Focus Registrational; Therapeutic Use
Acronyms PLATINUM-SV

Most Recent Events

02 Feb 2017 Status changed from active, no longer recruiting to completed.
01 Nov 2013 Interim results (PLATINUM SV and PLATINUM LL trials ) presented at the 25th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
18 May 2012 Two-year results were reported in a Boston Scientific Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight